vimarsana.com

Latest Breaking News On - புற்றுநோய் ஜெநெடிக்ஸ் - Page 7 : vimarsana.com

Vyant Bio Announces Investor Webcast to Provide Updates Post Merger between Cancer Genetics and StemoniX

Vyant Bio Announces Investor Webcast to Provide Updates Post Merger between Cancer Genetics and StemoniX CHERRY HILL, N.J., April 01, 2021 (GLOBE NEWSWIRE) Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners as well as for the proprietary pipeline of the Company. Today, Vyant Bio announced that an investor webcast will be hosted on Tuesday, April 6, 2021. Jay Roberts, Chief Executive Officer of Vyant Bio, will discuss corporate, scientific, and operational updates in relation to the Company’s recent merger between the predecessor, Cancer Genetics, Inc., and StemoniX, Inc. Mr. Roberts will be joined on the call by Vyant Bio’s Chief Innovation Officer, Ping Yeh, and Chief Financial Officer, Andy LaFrence. Please also visit the Investors’ section of the Vyant Bio web site for

Cancer Genetics to Present at the Annual 33rd ROTH Conference

Registration:  Mr. Roberts will highlight the Company s recent transformational business strategy, including the Company’s proposed merger with StemoniX, Inc., and elaborate on the broader going- forward corporate vision. If you are an investor and would like to attend the Company’s presentation, please click on the following link (https://www.meetmax.com/sched/event 70981/conference register.html) to register for the Annual 33 rd ROTH Conference. Once your registration is confirmed, you will be prompted to log into the conference website and will be able to request a one-on-one meeting with the Company. Cancer Genetics will also be available for outside virtual 1:1 meetings both during and after the Virtual Annual 33

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.